Grundlæggende statistik
| LEI | 549300VRD2QO80WBOP18 |
| CIK | 1720580 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adicet Bio, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi |
|
| May 13, 2026 |
As filed with the Securities and Exchange Commission on May 13, 2026 As filed with the Securities and Exchange Commission on May 13, 2026 Registration No. |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 13, 2026 |
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients with a minimum of six months follow-up U. |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2026 |
2025 Annual Report www.adicetbio.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2026 |
Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: [], 2026 Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holder |
|
| April 28, 2026 |
FORM 8-K Item 3.02 Unregistered Sales of Equity Securities. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 19, 2026 |
Adicet Bio, Inc. 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 Adicet Bio, Inc. 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 March 19, 2026 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 12, 2026 (File No. 333-294265), as amended Ladies and Gentlemen: Pur |
|
| March 18, 2026 |
March 18, 2026 Chen Schor Chief Executive Officer Adicet Bio, Inc. 131 Dartmouth Street, 3rd Floor Boston, MA 02116 Re: Adicet Bio, Inc. Registration Statement on Form S-3 Filed March 12, 2026 File No. 333-294265 Dear Chen Schor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We |
|
| March 12, 2026 |
Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Adicet Bio, Inc.(“Adicet,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate |
|
| March 12, 2026 |
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory alignment with the FDA enabling outpatient dosing of prula-cel for lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients in ongoing and future clinical studies Regulatory filing for ADI‑212 in metastatic castration‑resistant prostate cancer (mCPRC) planned for 3Q/2026; enrollment expected to begin 4Q/2026 pending regulatory clearance REDWOOD CITY, Calif. |
|
| March 12, 2026 |
Exhibit 10.32 FIFTH AMENDMENT TO LEASE This Fifth Amendment to Lease (the "Agreement") is entered into as of November 19, 2025 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts and circ |
|
| March 12, 2026 |
As filed with the Securities and Exchange Commission on March 12, 2026. As filed with the Securities and Exchange Commission on March 12, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| March 12, 2026 |
ADICET BIO, INC., Dated as of [●], 202[●] Senior Debt Securities Exhibit 4.2 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGIS |
|
| March 12, 2026 |
ADICET BIO, INC., Dated as of [●], 202[●] Subordinated Debt Securities Exhibit 4.3 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 12, 2026 |
Calculation of Filing Fee Tables Calculation of Filing Fee Tables S-8 Adicet Bio, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Second Amended and Restated 2018 Stock Option and Incentive Plan Common stock, par value $0.0001 per share Other 536 |
|
| March 12, 2026 |
Calculation of Filing Fee Tables Calculation of Filing Fee Tables S-3 Adicet Bio, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Ef |
|
| March 12, 2026 |
As filed with the Securities and Exchange Commission on March 12, 2026 Registration No. |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. ( |
|
| March 12, 2026 |
RESTATED CERTIFICATE OF INCORPORATION ADICET BIO, INC. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. Adicet Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Adicet Bio, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was July 5, 2 |
|
| January 7, 2026 |
FORM 8-K Item 7.01. Regulation FD Disclosure. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 07, 2026 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 29, 2025 |
FORM 8-K Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 29, 2025 |
Adicet Bio Announces Reverse Stock Split Adicet Bio Announces Reverse Stock Split REDWOOD CITY, Calif., December 26, 2025 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0 |
|
| December 29, 2025 |
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ADICET BIO, INC. CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. |
|
| December 19, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adice |
|
| November 5, 2025 |
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained reductions in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician’s Global Assessment (PGA), improved renal function, and favorable safety and tolerability profile as of the August 31, 2025 data cut-off date Company plans to request a meeting with U. |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2025 |
Leaders in Developing Allogeneic γδ1 CAR-T Cell Therapies to Fight Autoimmune Diseases and Cancer γδ= Gamma delta; CAR= Chimeric antigen receptor Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc. |
|
| October 7, 2025 |
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- - As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid |
|
| October 7, 2025 |
Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: [], 2025 Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holder |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2025 |
Exhibit 99.3 Pipeline Chart AAV= Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis; IIM= Idiopathic inflammatory myopathy; LN= Lupus nephritis; mCRPC= Metastatic castration-resistant prostate cancer; PSMA= Prostate specific membrane antigen; RA= Rheumatoid arthritis; SLE= Systemic lupus erythematosus; SPS= Stiff person syndrome; SSc= Systemic sclerosis. Timing subject to site a |
|
| October 7, 2025 |
70,001,000 Shares of Common Stock Pre-Funded Warrants to Purchase 10,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-285609 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 6, 2025) 70,001,000 Shares of Common Stock Pre-Funded Warrants to Purchase 10,000,000 Shares of Common Stock We are offering 70,001,000 shares of our common stock, par value $0.0001 per share (the common stock), and, in lieu of common stock to certain investors that so choose, pre-funded w |
|
| October 7, 2025 |
Exhibit 1.1 70,001,000 Shares And Pre-Funded Warrants to Purchase 10,000,000 Shares Adicet Bio, Inc. UNDERWRITING AGREEMENT October 7, 2025 JEFFERIES LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule A attached hereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 |
|
| August 7, 2025 |
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary clinical data for ADI-001 in 2H/2025 Enrollment now open for patients with idiopathic inflammatory myop |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio |
|
| August 7, 2025 |
LICENSE AND COLLABORATION AGREEMENT Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of May 16th, 2023 (the “Effective Dat |
|
| August 7, 2025 |
NON-EXCLUSIVE LICENSE AGREEMENT Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. NON-EXCLUSIVE LICENSE AGREEMENT THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of July 9, 2024 (the “Effective Date |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 25, 2025 As filed with the Securities and Exchange Commission on July 25, 2025 Registration No. |
|
| July 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc. |
|
| July 23, 2025 |
Adicet Bio, Inc. Pipeline Chart, as of July 23, 2025. Exhibit 99.1 |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 13, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 6, 2025 |
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 REDWOOD CITY, Calif. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2025 |
2024 Annual Report www.adicetbio.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 29, 2025 |
ACTIVE/129084123.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 17, 2025 |
Adicet Bio Appoints Michael Grissinger to the Board of Directors -Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions- REDWOOD CITY, Calif. & BOSTON – April 17, 2025 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoi |
|
| April 11, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 18, 2025 |
Up to $100,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-285609 PROSPECTUS Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (Jefferies) relating to shares of our common stock offered by this prospectus. As of the date of this prospectus, the Company has issued no shares of its common stock under the Sales Agreement |
|
| March 12, 2025 |
Adicet Bio, Inc. 131 Dartmouth Street, Floor 3 Boston, Massachusetts 02116 Adicet Bio, Inc. 131 Dartmouth Street, Floor 3 Boston, Massachusetts 02116 March 12, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 6, 2025 (File No. 333-285609), as amended Ladies and Gentlemen: Pursua |
|
| March 11, 2025 |
March 11, 2025 Chen Schor Chief Executive Officer Adicet Bio, Inc. 131 Dartmouth Street, 3rd Floor Boston, MA 02116 Re: Adicet Bio, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285609 Dear Chen Schor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025. As filed with the Securities and Exchange Commission on March 6, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe |
|
| March 6, 2025 |
Second Amendment to the 2022 Inducement Plan. Second Amendment to the 2022 Inducement Plan A. The Adicet Bio, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,750,000 shares, subject to adjustment as provided in Section 3(c).” B. Th |
|
| March 6, 2025 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities ACTIVE/136663340.1 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/136663340.1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 6, 2025 |
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25 Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25 Initiation of |
|
| March 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adicet Bio, Inc. |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc. |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. ( |
|
| March 6, 2025 |
Exhibit 4.3 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities ACTIVE/136663339.1 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/136663339.1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 |
|
| March 6, 2025 |
Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Adicet Bio, Inc.(“Adicet,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 19, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 19, 2024 |
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects to share preliminary Phase 1 clinical data in the first half of 2025 REDWOOD CITY, Calif. |
|
| November 27, 2024 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 18, 2024 |
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) expected in 2H25 REDWOOD CITY, Calif. |
|
| November 18, 2024 |
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 REDWOOD CITY, Calif. |
|
| November 15, 2024 |
EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Eighth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of November 8, 2024, by and between BANC OF CALIFORNIA, a California state chartered bank (formerly known as Pacific Western Bank) (“Bank”) and ADICET THERAPEUTICS, INC. |
|
| November 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2024 |
EX-99.1 2 tm2427451d8ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| November 14, 2024 |
ACET / Adicet Bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d8sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 14, 2024 |
ACET / Adicet Bio, Inc. / RTW INVESTMENTS, LP - ADICET BIO, INC. Passive Investment SC 13G/A 1 p24-3191sc13ga.htm ADICET BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the ap |
|
| November 14, 2024 |
ACET / Adicet Bio, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 acet1015245sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| November 14, 2024 |
ACET / Adicet Bio, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 14, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Adicet Bio, Inc. and further agree to the filing of this a |
|
| November 13, 2024 |
SC 13G/A 1 aceta3111224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adice |
|
| November 6, 2024 |
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202. |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 6, 2024 |
Form of Stock Option Cancellation Agreement. STOCK OPTION CANCELLATION AGREEMENT This STOCK OPTION CANCELLATION AGREEMENT (the “Agreement”) is made and entered into as of , 2024 (the “Effective Date”), by and between (the “Optionee”) and Adicet Bio, Inc. |
|
| October 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 16, 2024 |
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome ADI-001 clinical development program now addresses six autoimmune diseases Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase 1 study in multiple autoimmune diseases in the first half of 2025 REDWOOD CITY, Calif. |
|
| October 8, 2024 |
ACET / Adicet Bio, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ADICET BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 007002108 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| September 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 30, 2024 |
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) Enrollment open for patients with LN; enrollment in SLE, SSC, and AAV expected to open in the fourth quarter of 2024 REDWOOD CITY, Calif. |
|
| September 19, 2024 |
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue -Results highlight ADI-001's potential as a best-in-class allogeneic cell therapy for autoimmune disease- -Webcast featuring Dr. |
|
| September 19, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 19, 2024 |
Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors REDWOOD CITY, Calif. & BOSTON – August 19, 2024 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. “We are ple |
|
| August 13, 2024 |
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), following recent U. |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio |
|
| July 10, 2024 |
ACET / Adicet Bio, Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Adicet Bio, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 007002108 - (CUSIP Number) June 30, 2024 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| July 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 8, 2024 |
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Redwood City, Calif. |
|
| June 24, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 24, 2024 |
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical study to evaluate safety and anti-tumor activity of ADI-270 in relapsed/ refractory RCC patients Phase 1 clinical study to be initiated in 2H 2024; preliminary clinical data expected in 1H 2025 REDWOOD CITY, Calif. |
|
| June 7, 2024 |
Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan, as amended. ADICET BIO, INC. SECOND AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the “C |
|
| June 7, 2024 |
CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 7, 2024 |
Adicet Bio, Inc. Restated Certificate of Incorporation RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. Adicet Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Adicet Bio, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was July 5, 2016 (the “Or |
|
| June 7, 2024 |
CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. |
|
| June 5, 2024 |
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis Redwood City, Calif. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2024 |
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in 2Q 2024 Strong balance sheet with $247. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 10, 2024 |
ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Candidate Designed for Multiple Solid and Hematological Cancer Indications 27th ASGCT Annual Meeting 2024 Baltimore, MD Shon Green, PhD VP, Nonclinical Development ADI-270: Designed to address multiple refractory cancers CAR utilizes CD27 as the binding domain and contains CD27 and 4-1BB costimulatory domains plus CD3ζ (3rd gen) Inacti |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 24, 2024 |
2023 Annual Report www.adicetbio.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 23, 2024 |
ACTIVE/129084123.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 22, 2024 |
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024 Preclinical data will be featured in oral presentation on May 10, 2024 REDWOOD CITY, Calif. |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 22, 2024 |
OPEN MARKET SALE AGREEMENT March 22, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Adicet Bio, Inc. |
|
| March 22, 2024 |
Up to $100,000,000 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2022) As Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| March 22, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 21, 2024 |
ACET / Adicet Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 Activist Investment SC 13D/A 1 ss3173481sc13da.htm AMENDMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel GP Ltd |
|
| March 21, 2024 |
EX-99.1 2 ss3173481ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 7 to the Schedule 13D, dated March 19, 2024, with respect to the common stock of Adicet Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the u |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc. |
|
| March 19, 2024 |
Industrious: MEMBERSHIP AGREEMENT Contract Date: January 19, 2024 This Membership Agreement (“Agreement”) is made by and between the Industrious entity or entities (“Industrious”) and the member (“Member”) set forth below: Industrious Member Name INDUSTRIOUS BOS 131 DARTMOUTH STREET LLC Company Name Adicet Bio Location Address 131 Dartmouth Street 3rd Floor Boston, MA 02116 Contact Name Nick Harvey Email nharvey@adicetbio. |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. ( |
|
| March 19, 2024 |
Adicet Bio, Inc. Compensation Recovery Policy. ADICET BIO, INC. COMPENSATION RECOVERY POLICY Adopted as of November 16, 2023 Adicet Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in acco |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
Adicet Bio, Inc. Insider Trading Policy. ADICET BIO, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Adicet Bio, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Policy”) is designed to prevent the mis |
|
| March 19, 2024 |
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Expanded clinical pipeline into autoimmune diseases with U. |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| February 27, 2024 |
ACET / Adicet Bio, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADICET BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 007002108 (CUSIP Number) FEBRUARY 23, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 14, 2024 |
ACET / Adicet Bio, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 o110244sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023** (Date of Event Which Requires Filing of This Statement) Check the appr |
|
| February 14, 2024 |
ACET / Adicet Bio, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 acet13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
ACET / Adicet Bio, Inc. / RTW INVESTMENTS, LP - ADICET BIO, INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2024 |
ACET / Adicet Bio, Inc. / MORGAN STANLEY - MS INITIAL Passive Investment SC 13G 1 AdicetBioIncACET.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Adicet Bio, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 007002108 - (CUSIP Number) December 31, 2023 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 7, 2024 |
EX-99.2 Exhibit 2 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Erica Herberg, Anat Holt |
|
| February 7, 2024 |
ACET / Adicet Bio, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Ad |
|
| February 7, 2024 |
ACET / Adicet Bio, Inc. / BlackRock Inc. Passive Investment us0070021086020724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Adicet Bio, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 007002108 - (CUSIP Number) January 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 5, 2024 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 5, 2024, is by and among RA Capital Management, L. |
|
| February 5, 2024 |
ACET / Adicet Bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) January 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 2, 2024 |
SC 13G/A 1 aceta220224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio Inc. (Name of Issuer) common stock (Title of Class of Securities) 007002108 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| January 31, 2024 |
ACET / Adicet Bio, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us0070021086013124.txt us0070021086013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Adicet Bio, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 007002108 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 29, 2024 |
EX-99.1 2 ss2965118ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to the Schedule 13D, dated January 25, 2024, with respect to the common stock of Adicet Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the |
|
| January 29, 2024 |
ACET / Adicet Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment SC 13D/A 1 ss2965118sc13da-adicet.htm AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 24, 2024 |
27,054,667 Shares of Common Stock Pre-Funded Warrants to Purchase 8,445,333 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263587 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2022) 27,054,667 Shares of Common Stock Pre-Funded Warrants to Purchase 8,445,333 Shares of Common Stock We are offering 27,054,667 shares of our common stock, par value $0.0001 per share, or the common stock, and, in lieu of common stock to certain investors that so choose, pre-funded wa |
|
| January 24, 2024 |
Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: January [], 2024 Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holder”) i |
|
| January 24, 2024 |
Adicet Bio, Inc. Announces Proposed Public Offering Adicet Bio, Inc. Announces Proposed Public Offering REDWOOD CITY, Calif. & BOSTON-Jan. 22, 2024- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stoc |
|
| January 24, 2024 |
Adicet Bio, Inc. Announces Pricing of Public Offering Adicet Bio, Inc. Announces Pricing of Public Offering REDWOOD CITY, Calif. and BOSTON, January 22, 2024 – Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, |
|
| January 24, 2024 |
27,054,667 Shares And Pre-Funded Warrants to Purchase 8,445,333 Shares Adicet Bio, Inc. |
|
| January 23, 2024 |
ACET / Adicet Bio, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 AdicetBioInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING ADICET BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 007002108 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH |
|
| January 22, 2024 |
Subject to completion, dated January 22, 2024 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| January 19, 2024 |
ACET / Adicet Bio, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 19, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 16, 2024 |
Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer January 16, 2024 γδ= Gamma delta; CAR= Chimeric antigen receptor Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc. |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 4, 2024 |
Program Target Potential Indication Discovery Preclinical IND-Enabling Phase 1 Ph 2/3 ADI-001 CD20 NHL ADI-001 CD20 Autoimmune ADI-270 CD70 (TGFβ-DNR) RCC & Other ST / Heme ADI-925* Tumor stress ligands Multiple Solid / Heme ADI-xxx PSMA (w/ Armor) mCRPC ADI-002+ GPC3 HCC Adicet Bio Pipeline *ADI-925 is an engineered Chimeric Adapter (CAd) γδ1 T cell product candidate targeting stress ligands, including MICA/MICB & ULBP1-6, expressed on malignant cells. |
|
| January 4, 2024 |
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 REDWOOD CITY, Calif. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2023 |
Exhibit 10.2 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (the "Agreement") is entered into as of July 31, 2023, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts and c |
|
| November 8, 2023 |
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 study Prioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2024 REDWOOD CITY, Calif. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adice |
|
| August 9, 2023 |
Adicet Bio, Inc. Inducement Non-Qualified Stock Option Agreement. NON-QUALIFIED STOCK OPTION AGREEMENT Adicet Bio, INC. INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT Name of Optionee: Nancy Boman, M.D., Ph.D. No. of Option Shares: 136,000 Option Exercise Price per Share: $18.18 Grant Date: November 30, 2022 Vesting Start Date: November 28, 2022 Expiration Date: November 29, 2032 Adicet Bio, Inc. (the “Company”) hereby grants to the Optionee named above an opti |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc. |
|
| August 9, 2023 |
Exhibit 10.2 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (the "Agreement") is entered into as of July 31, 2023, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts and c |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio |
|
| August 9, 2023 |
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 11, 2023 |
Adicet Announces Appointment of Katie Peng to the Board of Directors Adicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif. |
|
| June 29, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| June 29, 2023 |
ACET / Adicet Bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership |
|
| June 26, 2023 |
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen re |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 5, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 5, 2023 |
ADICET BIO, INC. SECOND AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the “C |
|
| June 5, 2023 |
SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this “Amendment”) is made and entered into as of May 30, 2023, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and ADICET THERAPEUTICS, INC. |
|
| May 18, 2023 |
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment (TME) ADI-270 demonstrated potent anti-tumor activity in CD70+ cancers and improved resilience to clearance from host immune targeting REDWOOD CITY, Calif. |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 9, 2023 |
Amended and Restated Non-Employee Director Compensation Policy ADICET BIO, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Adicet Bio, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi |
|
| May 9, 2023 |
Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231. |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 18, 2023 |
2022 Annual Report www.adicetbio.comCorporate Information Board of Directors Executive Officers Carl L. Gordon, Ph.D., CFA Managing Partner and Co-Head of Global Private Equity, OrbiMed Advisors LLC Blake Aftab, Ph.D. Chief Scientific Officer Steve Dubin, J.D. Principal, SDA Ventures LLC Francesco Galimi, M.D., Ph.D. Chief Medical Officer Jeffrey A. Chodakewitz, M.D. Director Nick Harvey Chief Fin |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 S-8 1 adicet2022s-8.htm S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or o |
|
| March 15, 2023 |
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress • Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023 • Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Adicet’s R&D Pipeline Event REDWOOD CITY, Calif. |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc. |
|
| March 15, 2023 |
First Amendment to the 2022 Inducement Plan A. The Adicet Bio, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,000,000 shares, subject to adjustment as provided in Section 3(c).” B. The |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. ( |
|
| March 15, 2023 |
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. |
|
| March 15, 2023 |
THIRD AMENDMENT TO LEASE This Third Amendment to Lease (the "Agreement") is entered into as of January 9, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC. |
|
| March 13, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Adicet Bio, Inc. and further agree to the filing of this agreement as an exhibit thereto. I |
|
| March 13, 2023 |
ACET / Adicet Bio Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 14, 2023 |
ACET / Adicet Bio Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994088913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2023 |
ACET / Adicet Bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADICET BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2023 |
ACET / Adicet Bio Inc / RTW INVESTMENTS, LP - ADICET BIO, INC. Passive Investment SC 13G/A 1 p23-0488sc13ga.htm ADICET BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the app |
|
| February 13, 2023 |
ACET / Adicet Bio Inc / BlackRock Inc. Passive Investment SC 13G 1 us0070021086021323.txt us0070021086021323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ADICET BIO INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 007002108 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 3, 2023 |
ACET / Adicet Bio Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING ADICET BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 007002108 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio Inc. (Name of Issuer) common stock (Title of Class of Securities) 007002108 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| December 23, 2022 |
ACET / Adicet Bio Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 12, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 12, 2022 |
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 02, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 8, 2022 |
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of December 2, 2022, by and between PACIFIC WESTERN BANK, a California state chartered bank (?Bank?) and ADICET THERAPEUTICS, INC. |
|
| November 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 10, 2022 |
Virtual R&D Event November 10, 2022 Virtual R&D Event November 10, 2022 Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bi |
|
| November 8, 2022 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TWIST BIOSCIENCE ANTIBODY DISCOVERY AGREEMENT This Antibody Discovery Agreement (?Agreement?) is entered into as |
|
| November 8, 2022 |
Up to $100,000,000 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254193 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 30, 2021) Up to $100,000,000 Common Stock We entered into a Capital On Demand™ Sales Agreement, dated March 12, 2021, or the Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we may offer and sell shares of our common stock, par value $0.0 |
|
| November 8, 2022 |
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual Meeting Company to host ADI-001 webcast event on December 11, 2022 at 9:00 a. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 3, 2022 |
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete response rate and sustained durability in patients, including those previously exposed to CAR T therapy 100% ORR and CR rate in four anti-CD19 CAR T relapsed patients ADI-001 continued to demonstrate a favorable safety and tolerability profile Clinical data will be presented during poster presentation at ASH Annual Meeting on Saturday, December 10, 2022, from 5:30 – 7:30 p. |
|
| October 17, 2022 |
ACET / Adicet Bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADICET BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 007002108 (CUSIP Number) October 5, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 5, 2022 |
Adicet Bio, Inc. Pipeline chart as of October 5, 2022. Exhibit 99.1 |
|
| October 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 05, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 11, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| August 11, 2022 |
Exhibit 2 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. |
|
| August 11, 2022 |
ACET / Adicet Bio Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Address and |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 10, 2022 |
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL, as of May 31, 2022 data-cut date ADI-001 received FDA Fast Track Designation Strong balance sheet with $304. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, In |
